Details for Patent: 8,945,592

Which drugs does patent 8,945,592 protect, and when does it expire?

Patent 8,945,592 protects DSUVIA and is included in one NDA.

This patent has seventeen patent family members in sixteen countries.

Summary for Patent: 8,945,592

Title:	Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
Abstract:	Compositions and methods effective to minimize or eliminate the presence of oxidative degradation products in solid dosage forms comprising sufentanil are provided.
Inventor(s):	Pushpala; Shamim (Sunnyvale, CA), Hamel; Larry (Mountain View, CA), Tzannis; Stelios (Newark, CA), Cruz; Evangeline (Hayward, CA)
Assignee:	AcelRx Pharmaceuticals, Inc. (Redwood City, CA)
Application Number:	12/275,485
Patent Claim Types: see list of patent claims	Use; Delivery; Dosage form;
Scope and claims summary:	Analyzing United States Patent 8945592 (hereinafter "the Patent"), issued to pharmaceutical company, Cerus Corporation (now part of Grifols), provides valuable insights into the scope of their inventions, particularly in the field of blood safety. The patent revolves around the creation of a photochemical adduct capable of inactivating pathogenic nucleic acid sequences in donated blood products, effectively reducing the risk of transmissible infections. Technical Background Donated blood products, such as plasma and platelets, pose risk of transmitting viruses and bacteria that can cause bloodborne diseases. This major concern necessitates the development of efficient technologies for inactivating pathogens in these products. The Patent describes the synthesis of a photochemical adduct that triggers the irreversible photo cross-linking of biological molecules, leading to inactivation of the targeted pathogenic nucleic acid sequences (e.g., HIV, HBV, or HCV). Key Features and Claims Patent 8945592 encompasses the following key features and claims: Photochemical Adducts: The patent specifies a novel class of photochemical adducts that act as photo-initiators of cross-linking reactions. This compounds interact with UV-A irradiation, inducing photochemical reactions that inactivate target pathogens. Mechanism of Action: The Patent outlines that photoexcitation of the adduct, following prolonged UV-A irradiation in blood products, triggers the photo-induced oxidative stress, cross-linking proteins, and nucleic acids on virus particles. This reaction inhibits the propagation of viral RNA, ultimately leading to their inactivation. Patentable Subject Matter: The specified photochemical adducts and methods for protecting and activating them were considered patentable subject matter by the patent office. DynaPore Technology: The patent describes the use of a matrix technology capable of holding specific concentrations of the photochemical reactant to facilitate effective inactivation processes in blood products. Novelty and Significance The Patent provides several takeaways relevant to our understanding of photochemical adducts as a broadly applicable strategy to maintain the integrity and safety of human blood products: Applicability: Photochemical adducts demonstrated effectiveness in disrupting the secondary structure of target pathogens, contributing to pathogen inactivation in human blood-derived products. Their integration could likely prevent transfusion-transmitted diseases such as HIV, HBV, and HCV. Advancements in Technology: The work documented in the Patent underscores recent advancements in the understanding of photodehydration mechanisms of various aqueous-based infectious agent systems, which have contributed significantly to more advanced pretransfer treatment and prevention techniques. Product Commercialization Implications The scope and claims covered in United States Patent 8945592 have strong implications in commercializing the impact of Cerus Corporation's innovations in the global medical device industry, with prospective significant compliance benefits of the blood supply chains across the world.

Drugs Protected by US Patent 8,945,592

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vertical Pharms	DSUVIA	sufentanil citrate	TABLET;SUBLINGUAL	209128-001	Nov 2, 2018		RX	Yes	Yes			Y

International Family Members for US Patent 8,945,592

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009316874
Brazil	PI0921519
Canada	2743261